{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:24:03Z","timestamp":1777890243575,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,12,23]],"date-time":"2009-12-23T00:00:00Z","timestamp":1261526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,12,23]],"date-time":"2009-12-23T00:00:00Z","timestamp":1261526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gyn\u00e4kol Geburtshilfliche Rundsch"],"abstract":"<jats:p>Fragestellung: K\u00f6nnen die Rezidivraten genitaler Papillomvirusinfektionen durch zus\u00e4tzlich zur Lokaltherapie systemisch verabreichtes Interferon alfa-2a gesenkt werden? Methoden: Von 63 Patientinnen erhielten 33 mit erstmals aufgetretener oder nur gering ausgepr\u00e4gter Papillomvirusinfektion (Monolokalisation) eine Lokaltherapie. Die anderen 30 Patientinnen mit rezidivierend aufgetretenen oder an mehreren Organen manifesten Infektionen wurden systemisch mit Interferon alfa-2a behandelt. Verabreicht wurden 3 Zyklen mit jeweils 12 \u00d7 106 IE Interferon alfa-2a pro Zyklus. Ergebnisse: F\u00fcr die verbleibenden 47 Patientinnen (von 16 Patientinnen gibt es keinen Follow-up) ergab sich ein mittlerer Follow-up von 1,3 Jahren in der lokal therapierten Gruppe (n = 23) und von 1,2 Jahren in der Gruppe mit adjuvanter Interferontherapie (n = 24). Es entwickelten unter Interferontherapie mit 21 % (5 von 24) signifikant weniger Patientinnen ein Rezidiv als mit 52% (12 von )23) unter ausschliesslicher Lokaltherapie. Schlussfolgerung: Die adjuvante systemische Therapie genitaler HPV-positiver L\u00e4sionen mit Interferon alfa-2a in Kombination mit Lokaltherapie scheint die Rezidivraten zu senken.<\/jats:p>","DOI":"10.1159\/000272489","type":"journal-article","created":{"date-parts":[[2009,12,24]],"date-time":"2009-12-24T03:16:40Z","timestamp":1261624600000},"page":"79-84","source":"Crossref","is-referenced-by-count":7,"title":["Lokaltherapie und adjuvante Interferontherapie bei genitalen Papillomvirusinfektionen"],"prefix":"10.1159","author":[{"given":"Jael","family":"Backe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kaesemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Martius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,12,23]]},"container-title":["Gyn\u00e4kologisch-geburtshilfliche Rundschau"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000272489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:33:30Z","timestamp":1777613610000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000272489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,23]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000272489","archive":["Portico"],"relation":{},"ISSN":["1018-8843","1423-0011"],"issn-type":[{"value":"1018-8843","type":"print"},{"value":"1423-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,23]]}}}